Inositol tetrakisphosphate limits NK cell effector functions by controlling PI3K signaling

Blood

Volumn 121, Issue 2, 2013, Pages 286-297

  Sauer, Karsten ^a   Park, Eugene ^b   Siegemund, Sabine ^a   French, Anthony R ^b   Wahle, Joseph A ^b   Sternberg, Luise ^a   Rigaud, Stephanie ^a   Jonsson, A Helena ^b   Yokoyama, Wayne M ^b   Huang, Yina Hsing ^b  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INOSITOL PHOSPHATE; INOSITOL TETRAKISPHOSPHATE; INOSITOL(1,3,4,5)TETRAKISPHOSPHATE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL DIFFERENTIATION; CELL EXPANSION; CELL FUNCTION; CELL KILLING; CELL MATURATION; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME INHIBITION; EXOCYTOSIS; GRANULE CELL; IMMUNE RESPONSE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TARGET CELL;

EID: 84872347788     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-05-429241     Document Type: Article

References (50)

1. Vivier E, Raulet DH, Moretta A, et al. Innate or adaptive immunity? The example of natural killer cells. Science. 2011;331(6013):44-49.
2. Romagné F, Vivier E. Natural killer cell-based therapies. F1000 Med Rep. 2011;3:9.
3. Terme M, Ullrich E, Delahaye NF, Chaput N, Zitvogel L. Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nat Immunol. 2008;9(5):486-494. (Pubitemid 351560517)
4. Kerr WG, Colucci F. Inositol phospholipid signaling and the biology of natural killer cells. J Innate Immun. 2011;3(3):249-257.
5. Vivier E, Ugolini S, Blaise D, Chabannon C, Brossay L. Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol. 2012;12(4):239-252.
6. Elliott JM, Yokoyama WM. Unifying concepts of MHC-dependent natural killer cell education. Trends Immunol. 2011;32(8):364-372.
7. Di Santo JP. Natural killer cell developmental pathways: a question of balance. Annu Rev Immunol. 2006;24:257-286.
8. Lanier LL. NK cell recognition. Annu Rev Immunol. 2005;23:225-274. (Pubitemid 40563170)
9. Raulet DH, Vance RE. Self-tolerance of natural killer cells. Nat Rev Immunol. 2006;6(7):520-531. (Pubitemid 43980524)
10. Hayakawa Y, Watt SV, Takeda K, Smyth MJ. Distinct receptor repertoire formation in mouse NK cell subsets regulated by MHC class I expression. J Leukoc Biol. 2008;83(1):106-111.
11. Orr MT, Lanier LL. Inhibitory ly49 receptors on mouse natural killer cells. Curr Top Microbiol Immunol. 2011;350:67-87.
12. Di Santo JP. Natural killer cells: diversity in search of a niche. Nat Immunol. 2008;9(5):473-475. (Pubitemid 351560514)
13. Höglund P, Brodin P. Current perspectives of natural killer cell education by MHC class I molecules. Nat Rev Immunol. 2010;10(10):724-734.
14. Joncker NT, Shifrin N, Delebecque F, Raulet DH. Mature natural killer cells reset their responsiveness when exposed to an altered MHC environment. J Exp Med. 2010;207(10):2065-2072.
15. Jonsson AH, Yang L, Kim S, Taffner SM, Yokoyama WM. Effects of MHC Class I Alleles on Licensing of Ly49A+ NK Cells. J Immunol. 2010;184(7):3424-3432.
16. Chiossone L, Chaix J, Fuseri N, Roth C, Vivier E, Walzer T. Maturation of mouse NK cells is a 4-stage developmental program. Blood. 2009;113(22):5488- 5496.
17. Hayakawa Y, Smyth MJ. CD27 dissects mature NK cells into two subsets with distinct responsiveness and migratory capacity. J Immunol. 2006;176(3):1517- 1524. (Pubitemid 43134295)
18. Watzl C, Long EO. Signal transduction during activation and inhibition of natural killer cells. Curr Protoc Immunol. 2010;Chapter 11:Unit 11.9B.
19. Lemmon MA. Membrane recognition by phospholipid-binding domains. Nat Rev Mol Cell Biol. 2008;9(2):99-111. (Pubitemid 351158910)
20. Jiang K, Zhong B, Gilvary DL, et al. Pivotal role of phosphoinositide-3 kinase in regulation of cytotoxicity in natural killer cells. Nat Immunol. 2000;1(5):419-425.
21. Tassi I, Cella M, Gilfillan S, et al. p110gamma and p110delta phosphoinositide 3-kinase signaling pathways synergize to control development and functions of murine NK cells. Immunity. 2007;27(2):214-227. (Pubitemid 47284932)
22. Huang YH, Sauer K. Lipid signaling in T-cell development and function. Cold Spring Harb Perspect Biol. 2010;2(11):a002428.
23. Caraux A, Kim N, Bell SE, et al. Phospholipase C-gamma2 is essential for NK cell cytotoxicity and innate immunity to malignant and virally infected cells. Blood. 2006;107(3):994-1002. (Pubitemid 43156297)
24. Regunathan J, Chen Y, Kutlesa S, et al. Differential and nonredundant roles of phospholipase Cgamma2 and phospholipase Cgamma1 in the terminal maturation of NK cells. J Immunol. 2006;177(8):5365-5376. (Pubitemid 44527609)
25. Tassi I, Presti R, Kim S, Yokoyama WM, Gilfillan S, Colonna M. Phospholipase C-gamma 2 is a critical signaling mediator for murine NK cell activating receptors. J Immunol. 2005;175(2):749-754. (Pubitemid 41094955)
26. Huang YH, Grasis JA, Miller AT, et al. Positive regulation of Itk PH domain function by soluble IP4. Science. 2007;316(5826):886-889. (Pubitemid 46764278)
27. Jia Y, Loison F, Hattori H, et al. Inositol trisphosphate 3-kinase B (InsP3KB) as a physiological modulator of myelopoiesis. Proc Natl Acad Sci U S A. 2008;105(12):4739-4744. (Pubitemid 351753816)
28. Jia Y, Subramanian KK, Erneux C, et al. Inositol 1,3,4,5- tetrakisphosphate negatively regulates phosphatidylinositol-3,4,5-trisphosphate signaling in neutrophils. Immunity. 2007;27(3):453-467. (Pubitemid 47432757)
29. Maréchal Y, Pesesse X, Jia Y, et al. Inositol 1,3,4,5- tetrakisphosphate controls proapoptotic Bim gene expression and survival in B cells. Proc Natl Acad Sci U S A. 2007;104(35):13978-13983.
30. Miller AT, Sandberg M, Huang YH, et al. Production of Ins(1,3,4,5)P(4) mediated by the kinase Itpkb inhibits store-operated calcium channels and regulates B cell selection and activation. Nat Immunol. 2007;8(5):514-521. (Pubitemid 46613424)
31. Pouillon V, Hascakova-Bartova R, Pajak B, et al. Inositol 1,3,4,5-tetrakisphosphate is essential for T lymphocyte development. Nat Immunol. 2003;4(11):1136-1143. (Pubitemid 37428042)
32. Wen BG, Pletcher MT, Warashina M, et al. Inositol (1,4,5) trisphosphate 3 kinase B controls positive selection of T cells and modulates Erk activity. Proc Natl Acad Sci U S A. 2004;101(15):5604-5609. (Pubitemid 38481203)
33. Sauer K, Cooke MP. Regulation of immune cell development through soluble inositol-1,3,4,5-tetrakisphosphate. Nat Rev Immunol. 2010;10(4):257-271.
34. Cassatella MA, Anegon I, Cuturi MC, Griskey P, Trinchieri G, Perussia B. Fc gamma R(CD16) interaction with ligand induces Ca2+ mobilization and phosphoinositide turnover in human natural killer cells. Role of Ca2+ in Fc gamma R(CD16)-induced transcription and expression of lymphokine genes. J Exp Med. 1989;169(2):549-567. (Pubitemid 19050650)
35. Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods. 2004;294(1-2):15-22. (Pubitemid 39626587)
36. Buitenhuis M, van der Linden E, Ulfman LH, Hofhuis FM, Bierings MB, Coffer PJ. Protein kinase B (PKB/c-akt) regulates homing of hematopoietic progenitors through modulation of their adhesive and migratory properties. Blood. 2010;116(13):2373-2384.
37. Barnett SF, Defeo-Jones D, Fu S, et al. Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. Biochem J. 2005;385(Pt 2):399-408. (Pubitemid 40165072)
38. Calleja V, Laguerre M, Parker PJ, Larijani B. Role of a novel PH-kinase domain interface in PKB/Akt regulation: structural mechanism for allosteric inhibition. PLoS Biol. 2009;7(1):e17.
39. Marti F, XuCW, Selvakumar A, Brent R, Dupont B, King PD. LCK-phosphorylated human killer cell-inhibitory receptors recruit and activate phosphatidylinositol 3-kinase. Proc Natl Acad Sci U S A. 1998;95(20):11810- 11815. (Pubitemid 28460496)
40. Rajagopalan S, Moyle MW, Joosten I, Long EO. DNA-PKcs controls an endosomal signaling pathway for a proinflammatory response by natural killer cells. Sci Signal. 2010;3(110):ra14.
41. Wang JW, Howson JM, Ghansah T, et al. Influence of SHIP on the NK repertoire and allogeneic bone marrow transplantation. Science. 2002;295(5562):2094-2097. (Pubitemid 34229475)
42. Wahle JA, Paraiso KH, Costello AL, Goll EL, Sentman CL, Kerr WG. Cutting edge: dominance by an MHC-independent inhibitory receptor compromises NK killing of complex targets. J Immunol. 2006;176(12):7165-7169. (Pubitemid 43849017)
43. Wahle JA, Paraiso KH, Kendig RD, et al. Inappropriate recruitment and activity by the Src homology region 2 domain-containing phosphatase 1 (SHP1) is responsible for receptor dominance in the SHIP-deficient NK cell. J Immunol. 2007;179(12):8009-8015.
44. Fortenbery NR, Paraiso KH, Taniguchi M, Brooks C, Ibrahim L, Kerr WG. SHIP influences signals from CD48 and MHC class I ligands that regulate NK cell homeostasis, effector function, and repertoire formation. J Immunol. 2010;184(9):5065-5074.
45. Banh C, Miah SM, Kerr WG, Brossay L. Mouse natural killer cell development and maturation are differentially regulated by SHIP-1. Blood. 2012;120(23):4583-4590.
46. Fayard E, Xue G, Parcellier A, Bozulic L, Hemmings BA. Protein kinase B (PKB/Akt), a key mediator of the PI3K signaling pathway. Curr Top Microbiol Immunol. 2010;346:31-56.
47. Jiang K, Zhong B, Ritchey C, et al. Regulation of Akt-dependent cell survival by Syk and Rac. Blood. 2003;101(1):236-244. (Pubitemid 36025913)
48. König S, Nimtz M, Scheiter M, Ljunggren HG, Bryceson YT, Jansch L. Kinome analysis of receptor-induced phosphorylation in human natural killer cells. PLoS One. 2012;7(1):e29672.
49. Khurana D, Arneson LN, Schoon RA, Dick CJ, Leibson PJ. Differential regulation of human NK cell-mediated cytotoxicity by the tyrosine kinase Itk. J Immunol. 2007;178(6):3575-3582. (Pubitemid 46417624)
50. Lowin-Kropf B, Kunz B, Beermann F, Held W. Impaired natural killing of MHC class I-deficient targets by NK cells expressing a catalytically inactive form of SHP-1. J Immunol. 2000;165(3):1314-1321. (Pubitemid 30604560)